Press Releases

  • 17-06-13 / CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines

    Patents granted for mRNA-based RSV vaccines as well as for vaccination of infants / newborns and elderly with mRNA-based vaccines such as Flu


    TÜBINGE...

    Read more
  • 17-05-19 / CureVac to Present at Upcoming International Investor Conferences

    TÜBINGEN, Germany, May 19, 2017 – CureVac AG, the most clinically ad-vanced mRNA company, today announced that the company will present at two...

    Read more
  • 17-05-02 / CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary

    TÜBINGEN, Germany, May 2, 2017 – CureVac AG, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based therapies, today announced...

    Read more
  • 17-01-20 / CureVac’s CEO, Ingmar Hoerr, Appointed by European Commission to High Level Group

    TÜBINGEN, Germany, January 20, 2017 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today...

    Read more
  • 17-01-11 / CureVac Provides Clinical Update at 35th Annual J.P. Morgan Healthcare Conference

    SAN FRANCICSO/TÜBINGEN (Germany), January 11, 2017 – CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based...

    Read more
  • 16-12-28 / CureVac to Present at the J.P. Morgan 35th Annual Healthcare Conference 2017

    TÜBINGEN, Germany, December 28, 2017 – CureVac, a clinical-stage biopharma-ceutical company pioneering the field of mRNA-based technology, announced...

    Read more
  • 16-12-05 / Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant
    • For the first time, evidence suggests the same vaccine formulation (RNAdjuvant®) may elicit similar potency in both cancer patients and healthy...
    Read more
  • 16-11-08 / CureVac Secures an Additional $29.5 Million From Two New Investors

    Baden-Württembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte and Landeskreditbank Baden-Württemberg invest in CureVac‘s development of...

    Read more
  • 16-11-08 / CureVac Receives Broad Patent for RNAntibody® Technology

    CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection...

    Read more
  • 16-10-11 / CureVac Appoints Pierre Kemula as Chief Financial Officer

    Mr. Kemula will join CureVac’s management board and will be responsible for leading the company’s financial and capital markets activities.

    Read more
  • 16-07-14 / Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines

    CureVac AG today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine

    Read more
  • 16-03-30 / CureVac Appoints Leading Experts to its Scientific Advisory Board

    CureVac today announced the expansion of its external Scientific Advisory Board (SAB) to guide the company in this important period of extensive...

    Read more
  • 16-03-18 / CureVac strengthens supervisory board to support global growth opportunities and mRNA product expansion

    CureVac today announced the appointment of three seasoned industry experts to its supervisory board

    Read more
  • 16-02-18 / CureVac announces “MERAN” has been approved by the World Health Organization as suffix for mRNA drug substances

    CureVac AG today announced that the World Health Organization (WHO) has approved “MERAN” as a suffix for mRNA drug substances

    Read more
  • 16-01-06 / CureVac to Present at the 34th Annual J.P. Morgan Healthcare Conference

    CureVac presenting at the leading healthcare conference following numerous financial, clinical and corporate milestones

    Read more
  • 15-11-03 / CureVac raises $110 Million in a private placement

    Further investment for development of mRNA products

    Read more
  • 15-09-10 / IAVI and CureVac Partner to Accelerate Development and Testing of AIDS Vaccine Candidates

    Novel HIV immunogens to be delivered via novel mRNA platform

    Read more
  • 15-09-10 / CureVac Establishes U.S. Operations in Cambridge, MA

    Company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines

    Read more
  • 15-08-04 / CureVac & Bill & Melinda Gates Foundation - Collaboration to Develop mRNA Vaccines Expands

    Third Program in Collaboration with Foundation to Develop Vaccine against Respiratory Syncytial Virus (RSV) on the basis of CureVac’s Proprietary...

    Read more
  • 15-07-07 / CureVac Announces Phase I/IIa Clinical Study Data

    Publication of clinical data of mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer

    Read more
  • 15-06-24 / CureVac Announces Study Publication in Molecular Therapy Demonstrating Wide-Ranging Benefits of Sequence-Optimized, Unmodified mRNAs

    Peer-Reviewed Data Indicate that CureVac’s RNArt® Technology Can Produce Therapeutically Relevant Protein Levels

    Read more
  • 15-03-05 / The Bill & Melinda Gates Foundation and CureVac Collaborate to Accelerate the Development of Transformative Vaccine Technology

    Equity investment and additional funding of several vaccine development programs

    Read more
  • 14-09-18 / Boehringer Ingelheim and CureVac announce collaboration to develop next generation lung cancer immunotherapy

    Boehringer Ingelheim obtains exclusive global rights for development and commercialisation of CureVac’s investigational therapeutic cancer vaccine...

    Read more
  • 14-07-01 / CureVac Signs an Exclusive License Agreement with Sanofi Pasteur to Develop and Commercialize an mRNA-based Prophylactic Vaccine

    Triggered by ongoing and very successful multi-year collaboration

    Read more
  • 14-03-10 / CureVac Wins Two Million EUR from Inaugural European Commission Vaccine Prize

    RNActive® Vaccines Offer Excellent Conditions for Cost-Effective Worldwide Distribution

    Read more
  • 13-12-16 / CureVac Completes Patient Recruitment for Phase IIb Clinical Trial of mRNA-based Prostate Cancer Treatment

    195 chemotherapy-naïve patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer in eight European countries...

    Read more
  • 13-11-05 / 1st International mRNA Health Conference in Tübingen Heralds a New Era in Modern Medicine

    Experts from Industry and Academia Discussed the Medical Potential of Messenger RNA (mRNA)

    Read more
  • 13-11-04 / CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer

    Ludwig and CRI will conduct up to five clinical studies of cancer immunotherapy combinations through their jointly coordinated CVC Trials Network...

    Read more
  • 13-10-03 / CureVac to Collaborate with Janssen on Development of mRNA-Based Influenza Vaccine

    Partners collaborate on the development of an influenza vaccine based on CureVac’s RNActive® technology

    Read more
  • 13-03-27 / CureVac Initiates Phase 2b Clinical Trial of its mRNA-Based Cancer Vaccine in Patients with Castration-Resistant Prostate Cancer

    Phase 2b trial will enroll up to 200 patients in eight European countries to study CV9104 in chemotherapy-naïve patients with asymptomatic or...

    Read more
  • 12-11-26 / Data Published in Nature Biotechnology

    CureVac’s RNActive® Technology demonstrates immunogenicity and protection against influenza virus Infection

    Read more
  • 12-11-15 / CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project

    Project co-funded by the U.S. Defense Advanced Research Projects Agency

    Read more
  • 12-09-18 / CureVac Secures €80 Million in Series D Financing

    One of Europe’s Largest Private Financing Rounds in Biotech

    Read more
  • 11-11-07 / CureVac presents clinical results of a Phase I/IIa trial in non-small cell lung cancer (NSCLC)

    Data of CV9201, an mRNA based cancer vaccine, presented at the 26th Annual SITC Meeting in Washington

    Read more

Your contact

Verena Lauterbach
Senior Manager Communications
T: +49 7071 9883 1756
contact via e-mail